Press Releases

Novermber 12, 2024 | Press Release

Porta Sophia Publishes Narrative Review Manuscript Summarizing Historical Evidence of 5-MeO-DMT as a Compound Used in Therapeutic Practice

Manuscript publication: bridging decades of publicly known therapeutic 5-MeO-DMT treatments with existing pharmaceutical and scientific knowledge-sharing frameworks

October 28, 2024 | 3rd Party Observation

Allen Greenspoon and Anthony Adili International Patent Application PCT/CA2023/051505 | Porta Sophia Files Third Party Observation

Patent application: oral formulations of psilocybin for enhanced absorption

September 30, 2024 | 3rd Party Submission

Atai Therapeutics Inc. U.S. Patent Application 18/487,841 | Porta Sophia Files Third Party Submission

Patent application: ester analogs and prodrugs of psilocin, and methods of treating various diseases

September 27, 2024 | 3rd Party Submission

GH RESEARCH IRELAND LIMITED U.S. Patent Application 18/675,614 | Porta Sophia Files Third Party Submission

Patent application: therapeutic use of 5-MeO-DMT for major depressive disorder

September 26, 2024 | 3rd Party Submission

CaaMTech Inc. U.S. Patent Application 18/392,759 | Porta Sophia Files Third Party Submission

Patent application: tryptamine derivatives and compositions for use in treating various diseases

September 25, 2024 | 3rd Party Submission

Beckley Psytech Ltd. U.S. Patent Application 18/365,699 | Porta Sophia Files Third Party Submission

Patent application: pharmaceutically acceptable salts of 5-MeO-DMT with X-Ray Powder Diffraction analysis

September 13, 2024 | 3rd Party Submission

Mind Medicine Inc. U.S. Patent Application 18/543,789 | Porta Sophia Files Third Party Submission

Patent application: synthesis of MDMA prodrugs through unscheduled intermediates

September 6, 2024 | 3rd Party Submission

Turtle Bear Holdings LLC U.S. Patent Application 18/498,563 | Porta Sophia Files Third Party Submission

Patent application: combinations of tryptamines and fungal compounds to treat neuroinflammation

September 3, 2024 | 3rd Party Submission

ATAI Life Sciences AG U.S. Patent Application 18/244,078 | Porta Sophia Files Third Party Submission

Patent application: therapeutic use of R-MDMA for stress related disorders

August 30, 2024 | Press Release

All Claims Rejected for Turtle Bear Holdings U.S. Applications 18/531,052 and 18/531,407 Describing Psilocybin Microdosing

Patent applications: psilocybin microdosing

August 29, 2024 | 3rd Party Submission

CaaMTech Inc. U.S. Patent Application 18/260,711 | Porta Sophia Files Third Party Submission

Patent application: protected tryptamines for therapeutic uses including inflammation

August 21, 2024 | 3rd Party Submission

Remy Biosciences, Inc. U.S. Patent Application 17/824,901 | Porta Sophia Files Third Party Submission

Patent application: transdermal delivery of psilocybin and psilocin

August 15, 2024 | 3rd Party Submission

Agnieszka Dorota Sekula U.S. Patent Application 18/500,921 | Porta Sophia Files Third Party Submission

Patent application: virtual reality protocols for psychedelic-assisted therapy

August 13, 2024 | 3rd Party Submission

New York University U.S. Patent Application 18/260,359 | Porta Sophia Files Third Party Submission

Patent application: preventing suicidal ideation in patients with life-threatening diseases

August 2, 2024 | 3rd Party Submission

Johns Hopkins University U.S. Patent Application 18/255,518 | Porta Sophia Files Third Party Submission

Patent application: iboga alkaloid compositions for treating neurological injuries

July 29, 2024 | 3rd Party Submission

Wesana Health Inc. U.S. Patent Application 18/254,705 | Porta Sophia Files Third Party Submission

Patent application: psilocybin compositions for the treatment of neurological conditions

July 26, 2024 | 3rd Party Submission

Wesana Health Inc. U.S. Patent Application 18/254,731 | Porta Sophia Files Third Party Submission

Patent application: psilocybin compositions for the treatment of migraine and related conditions

July 10, 2024 | 3rd Party Submission

Soneira Inc. PBC & Leland Stanford Junior University U.S. Patent Application 18/467,324 | Porta Sophia Files Third Party Submission

Patent application: compositions of iboga alkaloids and methods of treatment

July 9, 2024 | 3rd Party Submission

Xpira Pharmaceuticals U.S. Patent Application 18/447,553 | Porta Sophia Files Third Party Submission

Patent application: optimized psilocybin formulations

June 12, 2024 | Press Release

Porta Sophia Files Third-Party Preissuance Submission against DMT Vape U.S. Patent Application

Patent applications: vape pen to administer DMT and other psychedelics

May 22, 2024 | Press Release

Porta Sophia Files European Patent Opposition Against GH Research Ireland Limited’s Patent on 5-MeO-DMT for Treating Major Depression

European Patent No. 3 927 337: Use of 5-MeO-DMT for Treating Major Depressive Disorder

May 21, 2024 | 3rd Party Submission

CaaMTech, Inc. U.S. Patent Application 18/248,577 | Porta Sophia Files Third Party Submission

Patent application: tryptamine derivatives and their therapeutic uses

May 8, 2024 | 3rd Party Observation and Submission

New York University Applications PCT/US2023/060478 and 18/153,140 | Porta Sophia Files Third Party Observation and Submission

Patent applications: psilocybin for treatment of Alcohol Use Disorder

May 7, 2022 | 3rd Party Observation and Submission

Reset Pharmaceuticals, Inc. Applications PCT/US2023/022033 and 18/196,567 | Porta Sophia Files Third Party Observation and Submission

Patent applications: subcutaneous injection of psilocybin or psilocin for treatment

May 3, 2024 | 3rd Party Submission

Turtle Bear Holdings Applications 18/531,052 and 18/531,407 | Porta Sophia Files Third Party Observation and Submission

Patent applications: microdosing psilocybin

April 30, 2024 | 3rd Party Submission

GoodCap Pharmaceuticals U.S. Patent Application 18/248,626 | Porta Sophia Files Third Party Submission

Patent application: Compositions for reducing inflammation to improve or maintain mental or physical health

April 26, 2024 | 3rd Party Submission

Complex Matrix Solutions U.S. Patent Application 18/467,857 | Porta Sophia Files Third Party Submission

Patent Application: Oral encapsulations of psilocybin and psychedelic compounds

April 24, 2024 | 3rd Party Submission

Mydecine Innovations Group Inc. U.S. Patent Application 18/026,780 | Porta Sophia Files Third Party Submission

Patent Application: Psilocybin in combination with MDMA to modulate 5HT2A receptor activity

April 16, 2024 | 3rd Party Submission

Terran Biosciences U.S. Patent Application 18/339,172 | Porta Sophia Files Third Party Submission

Patent application: Tryptamine combinations with 5-HT2A antagonists

April 16, 2024 | 3rd Party Submission

Yale University U.S. Patent Application 18/308,357 | Porta Sophia Files Third Party Submission

Patent application: Treatment of depressive disorders with intravenous DMT compounds

April 1, 2024 | 3rd Party Submission

Universitatsspital Basel Patent Application 18/336,724 | Porta Sophia Files Third Party Submission

Patent application: Psychedelic dosing method for treating psychiatric conditions

March 21, 2024 | 3rd Party Submission

MiHKAL GmbH U.S. Patent Application 18/024,517 | Porta Sophia Files Third Party Submission

Patent Application: novel safrylamine derivatives having prodrug properties

March 20, 2024 | 3rd Party Submission

CaaMTech, Inc. Patent Application 18/350,103 | Porta Sophia Files Third Party Submission

Patent application: 5-MeO-DALT compounds

March 14, 2024 | 3rd Party Submission

Mind Medicine, Inc. U.S. Patent Application 18/196,992 | Porta Sophia Files Third Party Submission

Patent application: Desoxyscaline derivatives for changing neurotransmission

March 6, 2024 | 3rd Party Submission

Psilera Inc. U.S. Patent Application 18/229,286 | Porta Sophia Files Third Party Submission

Patent application: Intranasal administration of DMT and DMT fumarate

February 21, 2024 | 3rd Party Submission

Mind Medicine, Inc. U.S. Patent Application 17/734,098 | Porta Sophia Files Third Party Submission

Patent Application: titrating psychedelic dosing regimen to reduce hallucination side effects

February 19, 2024 | 3rd Party Submission

Louisiana State University U.S. Patent Application 17/984,011 | Porta Sophia Files Third Party Submission

Patent Application: Serotonin receptor agonists for ameliorating pathogenesis

February 15, 2024 | 3rd Party Submission

ATAI Life Sciences AG U.S. Patent Application 18/116,195 | Porta Sophia Files Third Party Submission

Patent Application: R-MDMA HCl polymorph synthesis and characterization

February 14, 2024 | Press Release

Porta Sophia Publishes in Harvard Law School’s Bill of Health

Case study of the psychedelic biotech company MindMed, Inc. and patent applications that infringe on the public domain

January 12, 2024 | 3rd Party Submission

Mind Medicine, Inc. U.S. Patent Application 18/186,764 | Porta Sophia Files Third Party Submission

Patent Application: R-MDMA enantiomer to treat broad range of disorders

January 10, 2024 | 3rd Party Submission

Diamond Therapeutics Inc. U.S. Patent Application 18/102,268 | Porta Sophia Files Third Party Submission

Patent Application: methods of treatment for neurological and neuropsychiatric conditions with LSD

January 10, 2024 | 3rd Party Submission

PSYRX LTD. U.S. Patent Application 18/003,561 | Porta Sophia Files Third Party Submission

Patent Application: Combination of ibogaine and antidepressant to treat psychiatric disorders

January 8, 2023 | 3rd Party Submission

Lobe Sciences LTD. U.S. Patent Application 18/009,161 | Porta Sophia Files Third Party Submission

Patent Application: Combination of MDMA and N-acetylcysteine to Treat PTSD and mTBI

November 20, 2023 | 3rd Party Submission

University of Zürich U.S. Patent Application 18/012,122 | Porta Sophia Files Third Party Submission

Patent Application: composition comprising DMT and harmine

October 30, 2023 | 3rd Party Submission

The Royal Institution for the Advancement of Learning and McGill University U.S. Patent Application 18/102,296 | Porta Sophia Files Third Party Submission

Patent Application: methods of treatment for neurological and neuropsychiatric conditions with LSD

October 30, 2023 | 3rd Party Observation and Submission

Mind Medicine, Inc. Applications PCT/US2022/033308 and 17/839,374, Porta Sophia Files Third Party Observation and Submission

Patent application: computer application for monitoring a psychedelic therapeutic session

October 12, 2023 | 3rd Party Submission

The Beckley Foundation U.S. Patent Application 17/905,549 | Porta Sophia Files Third Party Submission

Patent Application: LSD for Treatment of Pain

October 9, 2023 | 3rd Party Submission

Emergex USA Corporation U.S. Patent Application 17/997,094 | Porta Sophia Files Third Party Submission

Patent application: transdermal delivery of psychedelics via microprojections

September 20, 2023 | 3rd Party Submission

Turtle Bear Holdings, LLC U.S. Patent Application 18/114,381 | Porta Sophia Files Third Party Submission

Patent application: treatment of depression with baeocystin, norbaeocystin, and psilocybin

September 14, 2023 | 3rd Party Submission

Terran Biosciences Inc. U.S. Patent Application 17/989,673 | Porta Sophia Files Third Party Submission

Patent application: solid formulations of empathogenic compounds

September 6, 2023 | 3rd Party Submission

Mind Medicine, Inc U.S. Patent Application 18/194,761 | Porta Sophia Files Third Party Submission

Patent application: oral lyophilized tablet immediate release LSD formulation

September 5, 2023 | 3rd Party Submission

Eleusis Health Solutions U.S. Patent Application 17/910,452 | Porta Sophia Files Third Party Submission

Patent application: enhancements to psychedelic therapy safety

September 1, 2023 | Application Abandoned

Application Abandoned for Pike Therapeutics Inc. U.S. Patent Application 17/231,553 Describing Transdermal Psychedelic Microdosing

Patent Application: Transdermal microdosing of psychedelics

August 18, 2023 | 3rd Party Observation

Beckley Psytech Limited International Patent Application PCT/GB2022/053123, Porta Sophia Files Third Party Observation

Patent Application: Method of Producing Polymorph A’ of Psilocybin

August 14, 2023 | 3rd Party Observation

Mind Medicine, Inc. International Patent Application PCT/US2022/040636, Porta Sophia Files Third Party Observation

Patent Application: oral lyophilized tablet immediate release LSD formulation

August 3, 2023 | 3rd Party Submission

Turtle Bear Holdings, LLC U.S. Patent Application 18/115,966 | Porta Sophia Files Third Party Submission

Patent application: norpsilocin and niacin to treat neurological disorders

July 31, 2023 | 3rd Party Submission

Lobe Sciences LTD U.S. Patent Application 17/916,855 | Porta Sophia Files Third Party Submission

Patent application: N-acetyl-cystine and psilocybin for traumatic brain injury and/or PTSD

July 8, 2023 | 3rd Party Submission

Orthogonal Thinker, Inc. U.S. Patent Application 17/912,821 | Porta Sophia Files Third Party Submission

Patent application: psilocybin compositions generated via tincture extraction

July 6, 2023 | 3rd Party Submission

The Regents of the University of California U.S. Patent Application 17/915,884 | Porta Sophia Files Third Party Submission

Patent application: monitoring neural and physiological status while using a psychedelic

July 5, 2023 | 3rd Party Observation

Eleusis Therapeutics Inc. International Patent Application PCT/US2022/043580, Porta Sophia Files Third Party Observation

Patent Application: LSD formulated in chewing gum

July 3, 2023 | Press Release

Porta Sophia Achieves Landmark Milestone: 50 Third-Party Interventions Filed

Porta Sophia Milestone: 50 Third-Party Interventions Filed

July 3, 2023 | 3rd Party Observation

Mind Medicine Inc. Patent Application PCT/US2022/026921, Porta Sophia Files Third Party Observation

Patent Application: method of treating pain using psychedelics

June 22, 2023 | Application Abandoned

Application Abandoned for Pharma America Holding U.S. Patent Application 17/525,248 Describing MDMA combined with Viagra® for enhanced sexual desire and ability

Patent Application: MDMA combined with Viagra® for enhanced sexual desire and ability

June 21, 2023 | 3rd Party Observation and Submission

University Hospital of Basel Applications PCT/IB2022/054049 and 17/734,601, Porta Sophia Files Third Party Observation and Submission

Patent application: LSD and psilocybin dosing system

June 21, 2023 | 3rd Party Observation and Submission

Pike Therapeutics Inc. Applications PCT/IB2022/057210 and 17/879,846, Porta Sophia Files Third Party Observation and Submission

Patent application: transdermal administration of sub-hallucinogenic dosages of psychedelics

June 15, 2023 | Claims Rejection

All Claims Rejected for ATAI Life Sciences U.S. Patent Application 17/941,648 Describing Ibogaine Co-Administration with a Metabolism Inhibitor for Safer Therapies

Patent Application: Ibogaine Co-Administration with a Metabolism Inhibitor for Safer Therapies

June 14, 2023 | 3rd Party Submission

ECP Pharma Application 18/045,843 | Porta Sophia Files Third Party Submission

Patent application: cannabidiol and psilocybin combinations to treat traumatic brain injuries

June 14,2023 | 3rd Party Submission

GH Research Ireland Limited Application 17/801,389 | Porta Sophia Files Third Party Submission

Patent application: 5-MeO-DMT aerosol for inhalation

June 12, 2022 | 3rd Party Submission

Psilothera Inc. Application 17/459,998 | Porta Sophia Files Third Party Submission

Patent application: method of providing psychedelic-assisted therapy via telehealth

June 09, 2023 | 3rd Party Observation and Submission

Mind Medicine Inc. Applications PCT/US2022/032601 and 17/835,501, Porta Sophia Files Third Party Submission and Observation

Patent application: 18-methoxycoronaridine to treat obesity 

June 08, 2023 | 3rd Party Submission

Mind Medicine, Inc Application 17/877,521 | Porta Sophia Files Third Party Submission

Patent application: psychedelic treatment of pain

June 07, 2023 | 3rd Party Submission

Mind Medicine, Inc Application 17/732,878, Porta Sophia Files Third Party Submission

Patent application: psychedelic treatment of pain

June 07, 2023 | 3rd Party Submission

Mind Medicine Inc. Applications 17/890,198 and PCT/US2022/040653, Porta Sophia Files Third Party Submission and Observation

Patent application: Immediate release D-lysergic acid diethylamide (LSD)

June 02, 2023 | 3rd Party Observation and Submission

ATAI Life Sciences Applications 17/957,851 and PCT/US2022/045336, Porta Sophia Files Third Party Submission and Observation

Patent application: 5-MeO-DMT and bufotenine to treat headache disorders

May 26, 2023 | 3rd Party Observation and Submission

ATAI Life Sciences Applications 17/941,648 and PCT/US2022/043102, Porta Sophia Files Third Party Submission and Observation

Patent application: ibogaine co-administration with a metabolism inhibitor for safer therapies

May 23, 2023 | Claims Rejection

All Claims Rejected for CaaMTech Inc. U.S. Patent Application 17/095,430 Describing Combinations of Serotonergic Drugs

Patent Application: combinations of serotonergic drugs

May 11, 2023 | 3rd Party Submission

SW Holdings, Inc Application 17/624,377 | Porta Sophia Files Third Party Submission

Patent application: metered dosing formulations for psychedelics

May 4, 2023 | 3rd Party Submission

Neonmind Biosciences Inc. Application 17/782,582, Porta Sophia Files Third Party Submission

Patent application: psilocybin to treat obesity, eating disorders, and their complications

April 26, 2023 | 3rd Party Observation and Submission

Panagiotakopoulos et al Applications 17/948,180 and PCT/US2022/044039, Porta Sophia Files Third Party Submission and Observation

Patent application: composition of psilocybin, psilocin, baeocystin and norpsilocin

April 20, 2023 | Claims Rejection

All Claims Rejected for Diamond Therapeutics Inc. US Patent Application 17/427,037 Describing 5HT Receptor Agonists at Sub-Hallucinogenic Levels as Neurological Treatment

Patent Application: 5HT Receptor Agonists at Sub-Hallucinogenic Levels as Neurological Treatment

April 18, 2023 | 3rd Party Observation

Universitätsspital Basel (University Hospital of Basel) Patent Application PCT/IB2022/052189, Porta Sophia Files Third Party Observation

Patent Application: Co-Treatment of Antidepressant and Psychedelic

April 12, 2023 | 3rd Party Submission

CaaMTech U.S. Patent Application 17/620,855, Porta Sophia Files Third Party Submission

Patent Application: Purified Ibogaine and Ibogaine Derivatives for the Treatment of Addiction and Depression

April 10, 2023 | 3rd Party Submission

Mind Medicine, Inc. U.S. Patent Application 17/833,829, Porta Sophia Files Third Party Submission

Patent Application: Psychedelics Taken with 5-HT2A Antagonists to Control Psychedelic Trip Duration

March 29, 2023 | 3rd Party Submission

Universitätsspital Basel (University Hospital of Basel) Application 17/692,105, Porta Sophia Files Third Party Submission

Patent Application: Co-Treatment of Antidepressant and Psychedelic

March 16, 2023 | Claims Rejection

All Claims Rejected for Universitätsspital Basel US Patent Application Describing Mescaline and Analogs to Treat Medical Conditions

USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty and non-obviousness

March 10, 2023 | Claims Rejection

All Claims Rejected for University of Maryland, Baltimore US Patent Application Describing Psilocybin and Ketanserin or Ritanserin to Treat Depression

USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty and non-obviousness

March 10, 2023 | 3rd Party Submission

Journey Colab Corp International Patent Application, Porta Sophia Files Third Party Submission

Patent Application: Mescaline for Treatment of Substance Use Disorders

March 6, 2023 | 3rd Party Submission

Porta Sophia Files Third-Party Preissuance Submission for Turtle Bear Holdings, LLC U.S. Patent Application

Patent Application: Psychedelics Combined With Lion's Mane Mushrooms and Monoamine Oxidase Inhibitors To Modulate Inflammation Caused by Infection

February 23, 2023 | Claims Rejection

All Claims Rejected for Universitätsspital Basel US Patent Application Describing MDMA to Enhance Emotional Effects of Psychedelics

USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty and non-obviousness

February 23, 2023 | 3rd Party Observation

Mind Medicine, Inc International Patent Application, Porta Sophia Files Third Party Observation

Psychedelic prior art library presents four documents challenging patentability of 23 application claims

February 17, 2023 | 3rd Party Submission

University of Maryland, Baltimore U.S. Patent Application, Porta Sophia Files Third Party Submission

Psychedelic prior art library presents three documents challenging patentability of all claims

January 30, 2023 | Press Release

Porta Sophia Responds to USPTO Request for Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights

January 23, 2023 | 3rd Party Observation

Universitätsspital Basel Patent Application, Porta Sophia Files Third Party Observation

Psychedelic prior art library presents 14 documents challenging patentability of all application claims

January 20, 2023 | 3rd Party Submission

University of Basel Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 13 documents challenging patentability of all application claims

January 12, 2023 | 3rd Party Submission

Arbormentis LLC U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents 26 documents challenging patentability of all claims

January 6, 2023 | 3rd Party Submission

Mind Medicine Inc. U.S. Patent Application, Porta Sophia Files Third-Party Preissuance Submission

Psychedelic prior art library presents seven documents challenging patentability of all claims